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Structured Abstract:   
Purpose of review:  
Anaesthesia and sedation are ubiquitous in contemporary medical practice. Developments in 
anaesthetic pharmacology are targeted on reducing physiological disturbance whilst maintaining or 
improving titrateability, recovery profile and patient experience. Remimazolam is a new short-acting 
benzodiazepine in the final stages of clinical development. 
Recent findings:   
Clinical experience with remimazolam comprises volunteer studies and a limited number of clinical 
investigations. In addition, laboratory investigations explore the implications of its “soft drug” 
pharmacology. 
Summary: 
Remimazolam provides effective procedural sedation with superior success rates and recovery 
profile when compared to midazolam. Comparisons with propofol are required. Preliminary studies 
suggest potential for using remimazolam as the hypnotic component of general anaesthesia. 
Definitive studies are awaited. As a benzodiazepine, remimazolam could be evaluated as an 
anticonvulsant and for intensive care sedation. 
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Remimazolam was developed to exploit in a benzodiazepine the esterase pharmacology successfully 
deployed in the opioid remifentanil, Figure 1. “Soft pharmacology”[1] offers precise control of drug 
effect by titration of boluses and infusion rate with rapid recovery when administration ceases. 
Current benzodiazepines cause minimal cardiorespiratory depression and the introduction of ester 
hydrolysis aims to combine several favourable characteristics in a single molecule i.e. the retention 
of benzodiazepine pharmacology with rapid degradation to an inactive metabolite.  
 
      
Figure 1. Midazolam, remimazolam and remifentanil. In remimazolam and remifentanil the 
introduction of an ester side group allows rapid hydrolysis[2] to inactive metabolites by 
carboxylesterase-1 (CES-1) mainly located in the liver . 
 
Metabolism 
Remimazolam is degraded to CNS7054 which appears to have negligible hypnotic activity. When 
human liver cells in a 3-D bioreactor were perfused with relevant concentrations of remimazolam to 
simulate prolonged anaesthesia or intensive care sedation, metabolism of remimazolam occurred at 
a stable rate over a five day period.[3] Gene expression of CES1 the enzyme that metabolises 





In 1985 Belfast Professor John Dundee wrote: “Ideally one would like a water-soluble, non-irritant, 
rapidly-acting, smooth induction agent, with no antanalgesic action. Cardiovascular and respiratory 
depression should be minimal with normal dosage.” and “A slight delay in onset would not be a 
major obstacle, provided this is predictable…”.[4] Human studies of remimazolam have evaluated its 
safety and efficacy as an hypnotic and collected data to address the Dundee challenge. 
 
Volunteer studies and early clinical trials confirm remimazolam to have typical benzodiazepine 
characteristics, Figure 2. Short infusions of remimazolam are hypnotic with dose related depth and 
duration of effect as measured by Bispectral Index, BIS or Modified Observer’s Assessment of 
Altertness/Sedation, MOAA/S scores. Heart rate and blood pressure were minimally perturbed. 
Pharmacokinetic and pharmacodynamic modelling of arterial remimazolam concentration and effect 














































Figure 2. A. Arterial concentrations (means) B. Bispectral Index, BIS (means) and  (C) Modified 
Observer’s Assessment of Alertness/Sedation Scale, MOAS/S (medians) in volunteers following a 
1min infusion of remimazolam 0.075mg/kg (solid line) or midazolam 0.075mg/kg (dashed line). 
Original data replotted with permission from Anesthesia and Analgesia, Vol 115, Antonik,L.J. et al., A 
placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, 
pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and 
basic pharmacokinetics, Pages 274-283.[7] Copyright 2012, with permission from Elsevier. 
 
Procedural sedation 
Endoscopy, interventional cardiology and interventional radiology are frequently facilitated by 
patient sedation.[9] Guidance on Safe Sedation emphasises the importance of selecting an 
appropriate sedative agent as well as setting standards for equipment, staffing, competencies and 
audit.[10] Adjunct opioid may be given, typically as a single small dose administered before the 
sedative. Benzodiazepines have the advantage of a specific antagonist, flumazenil. Although the safe 
administration of low-dose propofol sedation by well-trained nurse sedationists has been described 
for selected diagnostic endoscopy procedures[11] the practice remains controversial.[12] Further, 
serious and relatively frequent morbidity has recently been reported in a large series of Australian 
patients receiving anaesthetist administered propofol to facilitate endoscopy.[13] Nevertheless, 
procedural sedation with propofol remains popular with patients and proceduralists because of its 
brief action and clear headed recovery.  
 
Clinical trials of procedural sedation using remimazolam (typically supplemented by an opioid) have 
explored whether this new drug can provide rapid onset sedation with prompt recovery whilst 





Diagnostic colonoscopy is a common procedure performed in specialist clinics as well as in hospitals. 
Efficient patient throughput with patient satisfaction is a high priority and propofol sedation, 
typically administered by medically qualified anaesthesiologists, is preferred over midazolam 
because of the rapid onset and offset of propofol’s sedative effect.  
 
A substantial increase in anaesthetist input to colonoscopy, typically to administer propofol, has 
been identified and challenged. In a database review of 4,623,218 outpatient colonoscopies the 
proportion with ‘anesthesia assistance’ increased from 16.7% to 58.1% between 2003 and 2018.[14] 
Conversely, a recent database review of 44,794 colonoscopies in sedated patients concluded that 
propofol sedation was associated with small improvements in procedural quality indicators.[15] An 
outstanding question is whether these marginal gains can be replicated without the need for an 
anaesthesiologist. Large trials of procedural sedation using remimazolam have involved non-
anaesthesiologist sedationists.[16, 17] 
 
In a Phase 3 study, 461 patients undergoing colonoscopy were randomized to one of three arms: (i) 
remimazolam 5mg with supplementary doses of 2.5mg, (ii) placebo (with midazolam rescue), or (iii) 
open label midazolam (dosed according to the US label).[17] All patients received fentanyl 50-75mcg 
before the sedative or placebo. The pre-specified primary outcome measure of successful 
colonoscopy without rescue medication was achieved for in 91.3%, 1.7%, and 25.2% of patients 
receiving remimazolam, placebo, and midazolam respectively. Patients receiving remimazolam 
experienced less hypotension and recovered sooner than those receiving midazolam. Comparisons 
with propofol are awaited. 
 
Bronchoscopy¶ 
Whereas colonoscopy without sedation is poorly tolerated, bronchoscopy is often performed 
without sedation using only topical anaesthesia. UK guidance in 2013 suggested offering patients the 
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option of sedation with a recommendation for non-anaesthetists to use midazolam rather than 
propofol.[18] However, the use of propofol in this context has increased and a recent meta-analysis 
concluded “Propofol sedation is able to reduce recovery time and shows similar safety compared 
with midazolam sedation during bronchoscopy”.[19]  When remimazolam, midazolam and placebo 
were compared in 446 patients undergoing flexible bronchoscopy (similar design as for colonoscopy 
described above), procedural success was 80.6, 32.9 and 4.8% respectively. Remimazolam was 
administered as a 5mg bolus supplemented by 2.5mg top-ups. Times to recovery of alertness and 
restoration of neuropsychiatric function were shorter with remimazolam than with midazolam.[20]  
 
Anaesthesia 
The use of benzodiazepines to provide the hypnotic component of general anaesthesia has been 
reported intermittently since the 1960’s. By 1982 a critical evaluation of available benzodiazepines 
as candidate anaesthetics identified diazepam, flunitrazepam and midazolam as offering induction 
within 1-2 minutes whilst commenting that great individual variation in induction doses and long 
acting residual effects were problematic.17 The favourable pharmacokinetics and pharmacodynamics 
of remimazolam now offer an opportunity to revisit this indication. 
 
Although clinical trials registries including clinicaltrials.gov list multiple clinical trials of remimazolam 
in general anaesthesia and several are described as completed, none have yet been reported in 
peer-reviewed publications. However, some data have been reported as conference abstracts.[21-
24] The detailed outcomes of these investigations are awaited and data describing onset and 
recovery times as well as arterial blood pressure will be especially interesting. Can remimazolam 
deliver the haemodynamic stability reported in earlier accounts of benzodiazepine anaesthesia with 





Unlike propofol, remimazolam sedation may be completely reversed by the benzodiazepine 
antagonist flumazenil. In a preliminary study, three volunteers were deliberately sedated to loss of 
consciousness with remimazolam 0.25mg/kg. Sedation was reversed within one minute by 
flumazenil 0.5mg without subsequent re-sedation.[25]  
 
Currently, the use of flumazenil after midazolam sedation is considered a red flag event suggesting 
overdosing and by implication poor clinical practice. Routine flumazenil reversal is discouraged 
because of the possibility of re-sedation.[26]  
The short duration of remimazolam effect suggests that a more liberal approach might be 
considered if supported by properly designed clinical investigations. To date the clinical studies of 
remimazolam have only used flumazenil reversal as part of the management of rare instances of 
slow recovery from sedation or anaesthesia. In such circumstances the benzodiazepine 
(remimazolam) has usually been accompanied by an opioid. Appropriately designed clinical studies 
could usefully explore whether planned incorporation of flumazenil into end of sedation/anaesthesia 
protocols could enhance patient recovery. 
 
TCI and closed loop delivery 
Target controlled infusion, TCI is in worldwide use for propofol anaesthesia and sedation except in 
the United States where it remains without regulatory approval. Where TCI is available it is generally 
preferred over manual control. TCI for remifentanil is also available although its advantages over 
manual infusion are less clear-cut. Arguably, TCI delivery of remifentanil is of marginal benefit.[27] 
Ultra-short acting drugs (norepinephrine for example) are easily titrated by simple adjustment of 
infusion rate and not susceptible to accumulation and are not generally delivered by TCI. The 
pharmacokinetics and pharmacodynamics of remimazolam are intermediate between those of 
propofol and remifentanil and we may reasonably expect remimazolam TCI to be useful.[5, 6] 
Simulations of remifentanil TCI suggest that it would achieve steady state after 10 minutes versus 60 
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minutes for remimazolam and longer for propofol.[6] The original pharmacokinetic model for 
remimazolam is recirculatory rather than mammillary and therefore not suitable for TCI using 
currently available equipment. However, development of a multi compartment mammillary PK/PD 
model including an effect site has been recently reported[5, 6] and we can expect to see 
remimazolam TCI developed in due course. 
 
Closed-loop anaesthesia and sedation require an appropriate measure of hypnosis to provide 
feedback into the infusion controller. Bispectral Index, BIS and other EEG derivatives have been used 
in for this purpose however no closed-loop system has been successfully commercialised or licensed 
to date. Whereas the BIS algorithm has been optimised to provide an approximately linear and 
monotonic response to increasing doses of propofol or volatile anaesthetic agents its calibration 
against benzodiazepines is less clear. A small number of benzodiazepine sedated patients were 
included within the original BIS development[28] however its value for estimating hypnosis in 
patients receiving remimazolam is not as clear and straight forward as for propofol. Likewise, in 
volunteers receiving remimazolam, the Narcotrend Index “showed a relatively weak and discordant 
relationship to the Modified Observer’s Assessment of Alertness and Sedation score”.[5] In general 
the EEG effects of benzodiazepines are somewhat different from those of volatile agents. After 
remimazolam administration commences there is frontal beta-activation followed by delta waves, a 
pattern seen with other intravenous agents.[29]  
 
Environmental impact 
Concerns about the anaesthetic contribution to climate change are rightly escalating.[30]  The 
inhalational anaesthetics, especially desflurane and nitrous oxide have unfavourable environmental 
profiles and their replacement by routine use of intravenous anaesthesia has been advocated. In this 




Onco-anaesthesia and neurotoxicity 
The effects of anaesthetic drugs on cancer progression and recurrence are currently the subject of 
much research. Likewise, the possibility of neonatal neurotoxicity has generated concern. However, 
without clear evidence of harm in clinical practice anaesthetists have been advised to continue their 
current practice including inhalational anaesthesia for patients undergoing cancer surgery[31] and 
appropriate general anaesthesia for neonates when necessary.[32] Given this background of 
uncertainty the benzodiazepine pharmacology of remimazolam gives no reason for concern whilst 
the relevant basic science and clinical research are executed. 
 
Avoidance of hypotension 
A recent review of the relationship between arterial blood pressure and organ dysfunction identified 
that 10 minutes or more with mean arterial pressure below 80 mm Hg may represent a threshold for 
organ injury by perioperative hypotension,[33] although further understanding the consequences of 
its different causes remains a priority.[34] Minimising hypotension therefore becomes a goal for 
clinicians and developers of new anaesthetics alike and has already been claimed for alfaxalone 
formulated in cyclodextrin.[35] Pioneers of benzodiazepine anaesthesia noted only modest changes 
in arterial blood pressure during induction[36, 37] and the potential for decreasing perioperative 
hypotension and its harms comprises one of the techniques greatest potential advantages., Whether 
remimazolam as an hypnotic has haemodynamic advantages over volatile anaesthetics or propofol 
requires careful evaluation, preliminary data are encouraging.[21-23, 38] 
 
Conclusion 
Clinical investigations of remimazolam suggest that it is a safe and efficacious sedative. As was the 
case when remifentanil was introduced, distinctive pharmacology may lead to novel applications 




Key points:  
• Remimazolam is a novel benzodiazepine ester susceptible to hydrolysis by carboxylesterase-
1 (CES-1) mainly located in the liver. 
• In randomised controlled trials of procedural sedation remimazolam shows quicker onset 
and offset of hypnotic effect than midazolam. 
• Preliminary reports suggest remimazolam may be used as the hypnotic opponent of a total 
intravenous anaesthesia, TIVA technique. 
• Remimazolam exhibits the cardiorespiratory stability typical of benzodiazepines and its 
effects can be fully reversed by flumazenil. 
• The pharmacokinetics and pharmacodynamics of remimazolam can be described using 
standard 3-compartment effect site models and the drug may be suitable for target 
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The important references from the period reviewed must have one or two bullets and an 
annotation. These are a key feature of Current Opinion journals. 
Bulleted references must 
• Have been published during the period reviewed by the issue (during the past year). 
• Have one bullet (*) for special interest and two bullets (**) for outstanding interest. 
• Be annotated with a brief description of the paper's importance. 
When referencing and annotating your own work from previously published material you are limited 
to one bullet point. 
Note: Any annotations on references from outside of the review period will be removed unless a 
justification is submitted to the journal office. 
An example of bulleted and annotated reference section is shown below. 
One bullet annotations: still to be done 
* Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell 
biomarkers in patients with systemic complications of primary Sjo¨ gren’s syndrome. Ann Rheum Dis 
2007; 66:351–357. 
This is the first clinical trial to demonstrate the efficacy of B-cell depletion in SjS. 
This article highlights the importance of B cells in the pathogenesis of SjS. 
Two bullet annotations: 
** Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B-cell activating factor of the TNF family 




This study describes the elevation in BAFF levels that occurs in serum of patients who have been 
treated with B-cell depleting agents. This observation may have important consequences, following 
treatment, in promoting the corruption of B-cell tolerance and leading to disease relapse. 
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